[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351129-105":59,"doc-detail-351129-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-targets-of-cervical-cancer-and-its-microenvironment-advances-in-treatment","Molecular Targets of Cervical Cancer and Its Microenvironment - Advances in Treatment","","Cervical cancer is among the most frequently diagnosed cancers in women worldwide, with substantial annual mortality despite the availability of preventive vaccines. Its pathophysiology is driven by high-risk HPV, disrupted cell proliferation signaling, and remodeling of the tumor immune microenvironment, producing identifiable molecular signatures. These mechanisms support targeted and immunotherapeutic strategies for advanced, recurrent, persistent, and metastatic disease, including angiogenesis-directed agents, antibody-drug conjugates, immune checkpoint inhibition, and therapeutic vaccines targeting E6/E7, though stronger clinical evidence is still required.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-targets-of-cervical-cancer-and-its-microenvironment-advances-in-treatment/351129/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-targets-of-cervical-cancer-and-its-microenvironment-advances-in-treatment/351129.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What molecular drivers underlie cervical cancer development according to the review?","Question",{"text":112,"@type":113},"High-risk HPV is the main culprit, along with altered cell proliferation signaling and modulation of the tumor immune microenvironment, which together shape distinct molecular signatures.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which targeted treatments are discussed for advanced or metastatic cervical cancer?",{"text":117,"@type":113},"The review highlights agents such as Bevacizumab (anti-angiogenesis via targeting angiogenesis factors) and Endostar (recombinant human endostatin). It also covers antibody-drug conjugates like Tisotumab Vedotin and notes that anti-angiogenic tyrosine kinase inhibitors had limited efficacy.",{"name":119,"@type":110,"acceptedAnswer":120},"How does immunotherapy and therapeutic vaccination fit into cervical cancer treatment?",{"text":121,"@type":113},"Immunotherapy is presented as a key modality using immune checkpoint inhibition (PD1, PD-L1, CTLA4). Therapeutic vaccines are investigated to enhance cell-mediated immunity against E6 and E7 proteins for localized disease, but more robust trials are needed before clinical use.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351129,1790688734,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Review  \nMolecular Targets of Cervical Cancer and Its Microenvironment: Advances in Treatment  \nJoe Youssef 1,*, Amal El Masri 1, Maya Atwi 1, Elio Ibrahim 2, Zahraa Salhab 1, Mohamad Badawi 1, Fatima Nazar 1, Jad El Masri 1 and Wassim Abou-Kheir 1, *  \nAcademic Editor: Christian Singer  \nReceived: 30 December 2025  \nRevised: 3 February 2026  \nAccepted: 5 February 2026  \nPublished: 9 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut,  \nBeirut 1107-2020, Lebanon; [axm09@mail.aub.edu](axm09@mail.aub.edu) (A.E.M.); [mya43@mail.aub.edu](mya43@mail.aub.edu) (M.A.);  \n[zs83@aub.edu.lb](zs83@aub.edu.lb) (Z.S.); [mkb30@mail.aub.edu](mkb30@mail.aub.edu) (M.B.); [fan12@mail.aub.edu](fan12@mail.aub.edu) (F.N.); [jse20@mail.aub.edu](jse20@mail.aub.edu) (J.E.M.)  \n2 Faculty of Medicine, Saint-Joseph University, Beirut 1104-2020, Lebanon; [elio.ibrahim@net.usj.edu.lb](elio.ibrahim@net.usj.edu.lb)  \n* [Correspondence: jmy06@mail.aub.edu](Correspondence: jmy06@mail.aub.edu) (J.Y.); [wa12@aub.edu.lb](wa12@aub.edu.lb) (W.A.K.)  \nSimple Summary  \nCervical cancer remains a frequently diagnosed cancer among women and a major cause of death, despite efforts to reduce its occurrence with the preventive vaccines. Thanks to a better understanding of the molecular processes that define cervical cancer, newer approaches to tackle this cancer have been developed to supplement the traditional surgery, chemotherapy, and radiation. These include drugs that target blood vessel growth, specific antibodies that deliver a toxic drug directly to the cancer site, and immunotherapy that mounts the body’s immune system against the cancer cells. In addition, therapeutic vaccines that can be administered after the development of local lesions are being investigated as an additional treatment possibility. This review aims to summarize these emerging therapies and ongoing clinical trials, highlighting advances in cervical cancer treatment.  \nAbstract  \nCervical cancer remains one of the most commonly diagnosed cancers in women worldwide, with an elevated number of associated annual deaths, even though effective preventive vaccines are available. The pathophysiology of cervical cancer is well understood, with high-risk HPV as the main culprit in carcinogenesis, in addition to cell proliferation signaling alteration and tumor immune microenvironment modulation. This understanding of the disease’s molecular signatures has led to the development of several lines of treatment, especially for advanced, recurrent, persistent, or metastatic disease. For instance, Bevacizumab, a monoclonal antibody targeting angiogenesis factors, as well as Endostar, a recombinant human endostatin, have been studied and shown to improve survival in advanced disease. In contrast, anti-angiogenic Tyrosine Kinase Inhibitors had limited efficacy. Furthermore, antibody-drug conjugates such as Tisotumab Vedotin allow to deliver a highly toxic payload directly to the tumor site by binding to tissue factor, which is highly expressed in cervical tumor cells. Moreover, immunotherapy has emerged as a key treatment modality in cervical cancer by inhibiting immune checkpoint inhibitors (PD1, PD-L1, and CTLA4). In addition, therapeutic vaccines have been investigated for the treatment of localized disease by enhancing cell-mediated immunity against E6 and E7 proteins. However, more robust clinical trials are needed before these vaccines can be effectively and safely used clinically. Finally, several ongoing trials are currently evaluating new therapeutic modalities and combinations of the currently available tools in the cervical cancer treatment armamentarium.  \nKeywords: cervical cancer; pathophysiology; targeted therapy; immunotherapy; therap","cbCaikiTvDi1SuDX","https://ap.wps.com/l/cbCaikiTvDi1SuDX","pdf",1541121,31,"English","# Introduction\n## Global burden of cervical cancer\n## Risk factors and HPV contribution\n## FIGO staging system","[{\"question\":\"What molecular drivers underlie cervical cancer development according to the review?\",\"answer\":\"High-risk HPV is the main culprit, along with altered cell proliferation signaling and modulation of the tumor immune microenvironment, which together shape distinct molecular signatures.\"},{\"question\":\"Which targeted treatments are discussed for advanced or metastatic cervical cancer?\",\"answer\":\"The review highlights agents such as Bevacizumab (anti-angiogenesis via targeting angiogenesis factors) and Endostar (recombinant human endostatin). It also covers antibody-drug conjugates like Tisotumab Vedotin and notes that anti-angiogenic tyrosine kinase inhibitors had limited efficacy.\"},{\"question\":\"How does immunotherapy and therapeutic vaccination fit into cervical cancer treatment?\",\"answer\":\"Immunotherapy is presented as a key modality using immune checkpoint inhibition (PD1, PD-L1, CTLA4). Therapeutic vaccines are investigated to enhance cell-mediated immunity against E6 and E7 proteins for localized disease, but more robust trials are needed before clinical use.\"}]","Molecular Targets of Cervical Cancer and Its Microenvironment - Advances in Treatment | PDF",1790092757,78,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/894d9ce382dba5965227d7175abf5205.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f6e1d51a0f63c2dd93f80af6e885b68.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a7c3dd90a4ffe1ed4fffc4c92afffe7.webp",981,693,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a85e0e9fcb7cb124ba9e23ffd0b74dc.webp",980,692]